Clinical Trials

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07486726 2026-03-20

Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia

Phase 1/2 Not yet recruiting

112 enrolled

Leukemia, Myeloid, Acute

NCT03471260 2026-03-11

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

96 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03862157 2026-03-11

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

40 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06548230 2026-03-09

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

40 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

70 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT02677922 2026-02-19

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

130 enrolled 38 charts

Leukemia, Leukemia, Myeloid, Acute

NCT07148180 2026-02-05

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

31 enrolled

Leukemia, Leukemia, Myeloid, Acute, Neoplasm, Residual, Hematologic Neoplasms

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

LymphoidOther hematologic neoplasmPlasma cell

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

MyeloidOther hematologic neoplasmThoracic

116 enrolled 36 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

24 enrolled 16 charts

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT04581512 2025-10-14

Study to Evaluate the Safety and Tolerability of EP0042

70 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05270200 2025-09-25

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

20 enrolled

Leukemia, Myeloid, Acute

NCT03850574 2025-08-26

TUSCANY

240 enrolled

Recurrence, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06508489 2025-08-22

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

7 enrolled

Leukemia, Myeloid, Acute

NCT04086264 2025-08-14

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

218 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

336 enrolled 48 charts 1 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06449482 2025-05-30

Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy

6 enrolled

Leukemia, Myeloid, Acute

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

LymphoidMyeloidOther hematologic neoplasm

17 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04730258 2025-05-18

TWT-202

72 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms

NCT01892371 2025-04-06

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

73 enrolled 12 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04980885 2025-03-03

A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia

68 enrolled

Leukemia, Myeloid, Acute

NCT06150040 2025-02-20

AML-NET

1 enrolled

Leukemia, Myeloid, Acute

NCT06746519 2024-12-24

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

135 enrolled

Leukemia, Myeloid, Acute

NCT02400281 2024-07-03

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

28 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT04629443 2024-06-06

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

17 enrolled 19 charts

Phase 1/2 Not yet recruiting

Neoplasms, Leukemia, Myeloid, Acute

NCT06387420 2024-04-29

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

180 enrolled

Leukemia, Myeloid, Acute

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Phase 1/2 Withdrawn

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT04358393 2024-02-01

A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS

69 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04485052 2023-10-23

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Phase 1/2 Suspended

222 enrolled

Leukemia, Myeloid, Acute

NCT03701295 2023-10-18

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

1 enrolled 6 charts

Leukemia, Myeloid, Acute

NCT02096042 2023-10-10

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

1 enrolled 3 charts

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03390296 2023-09-05

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

50 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT03932318 2023-07-20

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Phase 1/2 Withdrawn

Leukemia, Myeloid, Acute

NCT05949762 2023-07-18

Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly

45 enrolled

Leukemia, Myeloid, Acute

NCT05140811 2023-05-24

A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

126 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

30 enrolled 29 charts

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

13 enrolled

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03072043 2022-01-24

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

55 enrolled 15 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02587598 2021-12-08

Study of INCB053914 in Subjects With Advanced Malignancies

LymphoidMyeloidOther hematologic neoplasmPlasma cell

97 enrolled 40 charts

Leukemia, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT05061147 2021-10-01

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

100 enrolled